Table 2.

Age-adjusted GM of arachidonic acid and linoleic acid–derived metabolites for ovarian cancer cases and controls in a nested case–control study in the PLCO Cancer Screening Trial

Control (N = 156)Ovarian cancer cases (N = 157)
Metabolites (pg/ml)GM (95% CI)GM (95% CI)P-value
Alpha-linoleic acid derived
 17-18-Epoxy-eicosatrienoic acids (17,18-EpETE)a827 (211–3,235)349 (65–1,862)0.40
 17-18-Dihydroxyeicosatetraenoic acids (17,18-DiHETE)1,759 (1,621–1,908)1,850 (1,705–2,006)0.39
 19-20-Epoxy-docosapentaenoic acid (19,20-EpDPE)3,044 (2,784–3,327)3,193 (2,927–3,482)0.45
 19-20-Dihydroxy-docosapentaenoic acid (19,20-DiHDPA)1,140 (1,055–1,232)1,190 (1,102–1,286)0.44
Linoleic acid/COX derived
 9-Hydroxyoctadecadienoic acid (9-HODE)5,988 (5,423–6,612)6,468 (5,859–7,140)0.28
 Trihydroxyoctadecenoic acids (9,10,13-THOME)2,685 (2,470–2,918)2,929 (2,696–3,183)0.15
Linoleic acid/LOX derived
 13-Hydroxyoctadecadienoic acid (13-HODE)6,018 (5,479–6,610)6,460 (5,883–7,093)0.29
 Trihydroxyoctadecenoic acids (9,12,13-THOME)1,343 (1,204–1,499)1,442 (1,293–1,608)0.37
Linoleic acid/P450 derived
 9-10-Epoxy-octadecenoic acid (9,10-EpOME)2,016 (1,092–3,723)1,426 (774–2,629)0.43
 9-10-Dihydroxyoctadecenoic acid (9,10-DHOME)4,593 (4,158–5,075)4,901 (4,437–5,412)0.37
 12–13-Epoxy-octadecenoic acid (12,13-EpOME))32,993 (29,346–37,092)35,060 (31,185–39,416)0.47
 12-13-Dihydroxyoctadecenoic acid (12,13-DHOME)5,041 (4,529–5,612)5,614 (5,045–6,247)0.16
Arachidonic acid/COX derived
 6-keto-Prostaglandin F (6-keto-PGF)1,453 (1,300–1,625)1,535 (1,373–1,716)0.50
 Prostaglandin F (PGF)1,367 (1,174–1,591)1,492 (1,284–1,735)0.42
 Prostaglandin E2 (PGE2)72.5 (59.1–89.0)72.7 (59.2–89.2)0.99
 Prostaglandin D2 (PGD2)a249 (180–343)211 (153–291)0.48
 Thromboxane B2 (TXB2)278 (191–404)275 (189–398)0.96
Arachidonic acid/LOX derived
 15-Hydroxyeicosatetraenoic acids (15-HETE)384 (347–425)390 (352–431)0.83
 12-Hydroxyeicosatetraenoic acids (12-HETE)4,844 (3,932–5,966)4,941 (4,014–6,082)0.89
 8-Hydroxyeicosatetraenoic acids (8-HETE)5,022 (4,551–5,541)5,325 (4,828–5,874)0.41
 5-Hydroxyeicosatetraenoic acids (5-HETE)661 (615–710)682 (635–733)0.54
 Leukotriene B4 (LTB-4)200 (169–236)255 (216–300)0.04
Arachidonic acid/P450 derived
 5–6-Dihydroxyeicosatrienoic acids (5,6-DHET)348 (322–376)352 (326–381)0.84
 8-9-Epoxyeicosatrienoic acids (8,9-EET)668 (612–729)670 (614–731)0.96
 8-9-Dihydroxyeicosatrienoic acids (8,9-DHET)226 (214–240)230 (218–244)0.66
 11-12-Epoxyeicosatrienoic acids (11,12-EET)709 (638–788)685 (617–761)0.65
 11-12-Dihydroxyeicosatrienoic acids (11,12-DHET)392 (370–414)403 (381–426)0.48
 14-15-Epoxyeicosatrienoic acids (14,15-EET)1,696 (1,511–1,905)1,805 (1,605–2,029)0.46
 14-15-Dihydroxyeicosatrienoic acids (14,15-DHET)523 (496–551)523 (497–551)0.98
Arachidonic acid/nonenzymatic derived
 11-Hydroxyeicosatetraenoic acids (11-HETE)190 (167–215)191 (168–216)0.94
 8-Iso-Prostaglandin F (8-iso-PGF)a718 (392–1,317)571 (302–1,080)0.59
  • GM, geometric mean.

  • aPGD2, 8-iso-PGF, and 17,18-EpETE had 90% of the samples below the detection limit. The GM and CI presented are for detectable samples only.